Top Biotech Companies (3,701)
For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As...
AgroFresh is a global leader in AgTech innovations and post-harvest freshness solutions. The company is dedicated to delivering integrated near- and post-harvest solutions from harvest to home, utilizing science-based solutions and data-driven technologies to measurably reduce fruit waste and conserve the planet's resources across the produce supply chain.
Curiox Biosystems is committed to enabling accurate biological analysis through automation. Next-generation methods and applications--including single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy--deserve a next-generation approach to preparing samples for analysis. That’s why Curiox invented Laminar Wash technology, the only sample preparation method that eliminates centrifugation and the problems it introduces. The methodology keeps cells in their...
Ketryx is the first and only connected application lifecycle management software for the life sciences industry. Our automation-based software enables companies building FDA-regulated software and AI-based applications to accelerate development through modern cloud-based tools while improving quality and compliance. Ketryx creates a real-time, and traceable, single source of truth by overlaying product development tools and connecting all items, risks, code,...
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition,...
Covestro's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Covestro holds top-tier, often #1, positions in polycarbonate and select specialty coating precursors, underpinned by global, multi-site capacity. Evidence also points to recognized strategic importance and deep technology/application know-how across polyurethane inputs, even if not the largest in every sub-market.
Future-Ready Strategy: Feedback suggests the company has clear climate-neutrality and circularity targets and is executing a multi-year transformation program alongside selective specialty acquisitions. These actions aim to shift the mix toward higher-value applications and position the portfolio for recovery when pricing and demand normalize.
Investor Backing & Capital Strength: Feedback suggests majority ownership by ADNOC/XRG and a completed capital increase provide stronger financial backing and optionality for investment. Regulatory clearances and integration steps indicate committed sponsorship that could support medium-term growth initiatives.
MOBILion’s technology makes it easy to separate, identify and analyze the most challenging molecules that other instruments fail to detect. Our higher resolution, faster analysis and simpler workflows reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. We make today’s treatment’s safer and more effective, empower tomorrow’s disease prediction and...
QbDVision is the leading Digital CMC™ Platform for pharmaceutical and biotech manufacturing. Created by a group of industry veterans with decades of drug development experience, we understand the challenges our platform was built to solve and are preparing our industry to deliver on its promise. We’re creating the modern digital tools our industry needs to realize the full potential of...
Immunai is a biotech company using single-cell genomics, machine learning, and software engineering to map and reprogram the immune system. Its AMICA data foundation and AI models support discovery and development of therapeutics, including applications in cancer, autoimmune disease, and immuno-oncology. The company partners with biopharmaceutical companies and research institutions to identify targets, biomarkers, mechanisms of action, and other clinically...
Microbial Discovery Group (MDG) is an R&D-driven product development and Bacillus fermentation company dedicated to developing and commercializing microbial solutions for industrial and environmental applications. Focused on addressing global challenges in health, environment, and food supply, MDG strives to 'Feed, Clean, Save the World' by leveraging real science and trusted processes to provide sustainable and innovative biological solutions for its...
MAT Research is a Leiden, Netherlands biotechnology company developing and supplying Monocyte Activation Test (MAT) solutions for pyrogen testing. Its rabbit-free, human-cell-based approach tests parenteral drugs for endotoxin and non-endotoxin contamination, mimics the human fever response, and supports pharmaceutical batch release, product-specific validation, and outsourced testing. The company’s mission is to improve patient safety while replacing animal-based tests and saving...
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve...
Avantor's Top Stability & Growth Strengths
Strong Market Position & Advantage: Disclosures describe one of the two largest global lab distributors via VWR with broad reach into research and production labs worldwide and deep embedment in biopharma workflows. This positions the company as a top-tier player in lab distribution and life-science consumables even if not the overall market leader.
Healthy Cash Flow: Recent updates highlight strong free-cash-flow conversion and deleveraging exiting 2024. Management emphasized ongoing cash generation alongside margin improvement.
Cost & Operational Efficiency: Management is executing multi-year cost programs with margin improvement evident in late 2024. Efficiency actions and portfolio focus are intended to support profitability despite uneven demand.
Healios K.K. is a leading Japanese clinical-stage biotechnology company specializing in regenerative medicine and cell therapy, developing innovative treatments for life-threatening conditions.
We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from...
Every Exelixis employee is united in an ambitious cause: to launch innovative medicines that give patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. After operating in the challenging biotech sector for more than 25 years, we have a proven track record of resiliency in the face of adversity....
Exelixis's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results and guidance indicate year-over-year revenue increases with momentum in early 2026 and a higher full-year outlook. Product sales from the cabozantinib franchise are the primary driver, with ex‑U.S. royalties contributing.
Strong Market Position & Advantage: Cabozantinib serves as a cornerstone TKI in RCC, with a guideline‑preferred first‑line combination and a multi‑indication label supporting durable commercial scale. Disclosures describe leadership within the U.S. RCC oral TKI segment and sustained global uptake through partners.
Future-Ready Strategy: Multiple pivotal studies and an FDA‑accepted NDA for zanzalintinib establish a path to a second commercial pillar beyond RCC. Investments in GI commercial infrastructure and 2026 data milestones reinforce preparedness for the next phase of growth.
DEKA is one of the leading research and development companies in the country and is the birthplace of some of the most innovative and life-changing products of our time. For over thirty years, DEKA Research & Development Corp. has made Manchester, New Hampshire home. Located about an hour from Boston, the beach, and the mountains, we are situated in the...
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
Catalyzing Innovation in Pharma with Data-driven Digital Products. The idea of DataZymes germinated with the realization that Pharma Commercial teams had few alternatives to the antiquated and inefficient solutions offered by traditional consulting and technology companies. Already a laggard in analytical maturity, the Pharma industry had been facing challenges to adapt to a Big Data world. We saw that the products offered...
StartX is a non-profit educational program and accelerator affiliated with Stanford University, dedicated to accelerating the development of Stanford-affiliated entrepreneurs through experiential education and collective intelligence.
Atrium Health Wake Forest Baptist is a nationally recognized academic medical center and health system based in Winston-Salem, North Carolina. Part of Advocate Health, the system integrates a tertiary-care hospital, community hospitals, and the Wake Forest University School of Medicine. It is dedicated to advancing healing through groundbreaking research, experiential medical education, and the delivery of compassionate, comprehensive healthcare services...
Cancer. Diabetes. Alzheimer’s. Heart Disease. Parkinson’s. The Jackson Laboratory (JAX) leads the search to cure diseases rooted in our DNA. Founded in 1929, we are an NCI-designated Cancer Center since 1983 and an independent 501(c)3 nonprofit research organization with over 90 years of experience in genetics and genomics research. JAX blends the brightest minds with state-of-the-art resources to accelerate discovery. Areas of Discovery...
The Jackson Laboratory's Top Stability & Growth Strengths
Strong Revenue Growth: Audited financials indicate operating revenue increased from about $620.0M in FY2023 to $657.8M in FY2024, with core genetic resources and clinical/research services also rising. Net assets and total assets also increased year over year.
Market Expansion: The NYSCF acquisition adding a New York campus, facility expansions in Maine and activity in Florida, and an international footprint including Japan signal geographic and capacity growth. Distribution of 13,000+ strains to thousands of organizations in dozens of countries underscores global reach.
Diversified Revenue Streams: Mouse sales and services remain the largest contributor, complemented by grants/contracts and investment income. This mix supports resilient top‑line growth across research and services.































